Analysts Issue Forecasts for TSE:GUD Q1 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Analysts at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for Knight Therapeutics in a research note issued on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts that the company will post earnings of $0.03 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

A number of other brokerages also recently weighed in on GUD. Stifel Nicolaus increased their price target on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group downgraded shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. Finally, Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of C$7.48.

Knight Therapeutics Trading Down 0.7 %

TSE:GUD opened at C$6.00 on Thursday. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. Knight Therapeutics has a 1-year low of C$5.09 and a 1-year high of C$6.45. The firm has a market capitalization of C$606.90 million, a price-to-earnings ratio of -20.03, a PEG ratio of -1,013.50 and a beta of 0.50. The business’s 50-day moving average price is C$5.73 and its two-hundred day moving average price is C$5.59.

Insider Transactions at Knight Therapeutics

In related news, insider Sime Armoyan sold 92,200 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of C$6.15, for a total transaction of C$567,030.00. Insiders have sold a total of 3,143,300 shares of company stock valued at $19,733,740 over the last 90 days. 45.62% of the stock is owned by company insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.